尿毒康合剂对腹膜透析患者腹膜透析效能及腹膜纤维化影响的临床观察

发布时间：2018-08-14 10:31

【摘要】：目的:探讨尿毒康合剂对腹膜透析患者的透析效能及腹膜纤维化的影响。方法:选取本院符合标准的终末期肾脏病腹膜透析患者82例,为2013年7月—2015年11月的病例。经伦理委员会批准并签订知情同意书,按随机对照设计、根据入选标准分为两组,分别41例,对照组采用维持性腹膜透析方案;研究组在此基础上采用尿毒康合剂治疗,均持续治疗3个月。治疗前和治疗3月时测定腹透液FN、TGF-β1值及血清HMGB-1、Hs-CRP、IL-6值,将Vu、RRF、KT/V、Vd作为评价透析效能的指标,同时对比两组间临床疗效,记录不良反应。结果:与治疗前比,两组治疗3月时腹透液FN、TGF-β1值降低,腹透液Vu、RRF、KT/V降低,Vd升高,血清HMGB-1、Hs-CRP、IL-6值降低(P0.05);与对照组比,研究组治疗3月时腹透液FN、TGF-β1值较低,腹透液Vu、RRF、KT/V较低,血清HMGB-1、HsCRP、IL-6值较低(P0.05);对照组有效率73.17%低于研究组90.24%(P0.05)。结论:尿毒康合剂能提高腹膜透析患者的透析效能,延缓肾功能恶化,具有抑制腹膜纤维化和肾脏微炎症的作用,是一种有效的治疗方案。
[Abstract]:Objective: to investigate the effect of Niaodukang mixture on dialysis efficacy and peritoneal fibrosis in peritoneal dialysis patients. Methods: 82 patients with end-stage renal disease peritoneal dialysis were selected from July 2013 to November 2015. According to the randomized controlled design, the patients were divided into two groups according to the selection criteria, 41 cases of each group were treated with maintenance peritoneal dialysis regimen, and the study group was treated with Niaodukang mixture on the basis of the approval of the ethics committee and the signing of the informed consent letter. All patients were treated continuously for 3 months. Before treatment and 3 months after treatment, the levels of TGF- 尾 1 in peritoneal dialysis fluid and serum HMGB-1 / Hs-CRPU IL-6 were measured. VuglrRFKT / VVd was used as an index to evaluate dialysis efficacy. The clinical efficacy of the two groups was compared and adverse reactions were recorded at the same time. Results: compared with before treatment, the values of FNNTGF- 尾 1 in peritoneal dialysate decreased in both groups at 3 months after treatment, and VuGB-1Hs-CRPIL-6 decreased in VuGB-1Hs-CRPIL-6, and the value of FNTGF- 尾 1 in peritoneal dialysate was lower in the study group than in the control group at 3 months after treatment, and the value of VuhrRFRRFKTrV in peritoneal dialysis was lower in the study group than that in the control group at 3 months after treatment, and the value of VuGB-1Hs-CRPIL-6 was lower in the study group than that in the control group at 3 months after treatment. The serum HMGB-1 HsCRPU IL-6 level was lower (P0.05), and the effective rate in the control group was 73.17% lower than that in the study group (90.24%, P0.05). Conclusion: Niaodukang mixture can improve the dialysis efficiency of peritoneal dialysis patients, delay the deterioration of renal function, inhibit peritoneal fibrosis and renal microinflammation, and is an effective treatment scheme.
【作者单位】：中山市中医院内四科;
【基金】：中山市科技计划项目(2015B1045)
【分类号】：R692.5

【相似文献】